21212 ⎘
Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
MICELLE COMPRISING AMPHIPHILIC PEPTIDE, AND ANTIGEN CARRIER NANOPARTICLE USING SAME
#2DUAL AND TRIPLE HAPTEN CONJUGATES, COMPOSITIONS, PROCESSES FOR MAKING, AND METHODS OF TREATMENT THEREWITH
#3BIHAPTENIZED AUTOLOGOUS VACCINES AND USES THEREOF
#4NONAUTOLOGOUS MULTI-STRESSED CANCER CELLS AND USES THEREOF FOR VACCINATING AND TREATING CANCERS
#5IN VITRO METHOD FOR DETECTION OF INFECTIONS CAUSED BY PSEUDOMONAS AERUGINOSA
#6Methods of rational nicotine hapten design and uses thereof
#7Antibodies Against Fentanyl and Fentanyl Analogs
#8Methods and compositions for substance use disorder vaccine formulations and uses thereof
#9METHODS AND COMPOSITIONS FOR STIMULATING THE IMMUNE SYSTEM
#10METHODS AND COMPOSITIONS FOR SUBSTANCE USE DISORDER VACCINE FORMULATIONS AND USES THEREOF
#11ANTI-OPIOID VACCINES
#12Therapeutic compositions and methods with cytokine signaling immunomodulators
#13ANTIBODIES AGAINST IMMUNOGENIC GLYCOPEPTIDES, COMPOSITIONS COMPRISING THE SAME AND USE THEREOF
#14DE-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
#15Methods of rational nicotine hapten design and uses thereof
#16Monoclonal antibody against muramyl peptides
#17NOVEL COCAINE HAPTENS AND NANOFIBER-BASED COCAINE VACCINES
#18Vaccines for use in the prophylaxis and treatment of influenza virus disease
#19Protein and peptide-free synthetic vaccines against type 3
#20Protein-cell conjugate, preparation method and use thereof
#21DE-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
#22Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
#23Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
#24Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
#25Immunogenic control of tumours and tumour cells
#26Methods of improving vaccine immunogenicity
#27Vaccines for use in the prophylaxis and treatment of influenza virus disease
#28Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
#29Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
#30De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
#31METHODS OF IMPROVING VACCINE IMMUNOGENICITY
#32Conjugates for the prevention or treatment of nicotine addiction
#33VACCINES FOR PREVENTION AND TREATMENT OF ADDICTION
#34Immunogenic control of tumours and tumour cells
#35De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
#36MIXED HAPTENIZED TUMOR CELLS AND EXTRACTS AND METHODS OF TREATING OR SCREENING FOR CANCER
#37RAPID GENERATION OF T CELL-INDEPENDENT ANTIBODY RESPONSES TO T CELL-DEPENDENT ANTIGENS
#38Mixed haptenized tumor cells and extracts and methods of treating or screening for cancer
#39Conjugate vaccines for non-proteinaceous antigens
#40Methods and compositions for pharmacologially controlled targeted immunotherapy
#41Low dose haptenized tumor cell and tumor cell extract immunotherapy